Abstract:Objective To analyze the clinical features and prognosis of the ipsilateral breast tumor recurrence ( IBTR) after breast conserving surgery. Methods From 1999 to 2013, 63 women with IBTR after breast conserving surgery were retrospectively reviewed. All patients had adequate information on tumor location both at first presentation and at recurrence, with or without regional recurrence or distant metastasis. The histologic changes between true local recurrence and elsewhere recurrence groups were compared. The local recurrence, the overall survival after IBTR (IBTR-OS), the disease-free survival after IBTR (IBTR-DFS) were also compared. Results All patients had undergone lumpectomy, including 38 cases with additional axillary lymph node dissection and 13 cases with sentinel lymph node biopsy. There were 11. 3％(7/63) cases received neoadjuvant systemic therapy, 68.3％ (43/63) had adjuvant radiotherapy, 60.3％(38/63) underwent adjuvant chemotherapy and 47.6％ (30/63) received hormonal therapy. Forty-five cases (71.4％) had recurrence in the same quadrant, and 18 cases (28.6％) had elsewhere recurrence. Compared with histology at presentation, 10.3％ of the patients (6/58) had different ones at recurrence and 28.9％ of patients (13/45) had different molecular subtypes. The conversion rate of estrogen receptor status (33.3％vs 9.5％, P=0. 012) and progesterone receptor status ( 56. 3％ vs 19. 0％, P=0. 005) in patients with elsewhere recurrence was significantly higher than that in patients with same quadrant recurrence. Fifty-nine cases had undergone surgery after IBTR, with 48 cases of secondary breast-conserving surgery and 11 cases of salvage mastectomy. The median time to IBTR of same quadrant recurrence and elsewhere recurrence groups were 26 months and 62 months (P=0.012), respectively. There were 84.4％ and 44.4％ cases who had local recurrence within 5 years after breast conserving surgery, respectively. Of all cases, the overall 5-year IBTR-OS and 5-year IBTR-DFS rates were 79.4％ and 60.4％, respectively. There were no significant differences in 5-year IBTR-OS (77.4％ vs. 83.6％, P=0.303) or 5-year IBTR-DFS (60.0％ vs. 62.8％, P=0.780) between same quadrant recurrence and elsewhere recurrence groups. Univariate analysis showed that pN0-1 (P<0.001), luminal subtype (P=0.026), adjuvant endocrine therapy (P=0.007) at first presentation, recurrent tumor < 3 cm ( P=0.036) and having surgery after IBTR( P=0.002) were favorable factors of IBTR-OS. pN0-1 (P<0.001) at first presentation, recurrent tumor stage Ⅰ-Ⅱ (P<0.001) and having surgery after IBTR ( P= 0. 001 ) were favorable factors of IBTR-DFS. There was no significant difference between second breast-conserving surgery and salvage mastectomy in IBTR-OS and IBTR-DFS ( P>0.05) . Conclusions The IBTR after breast conserving surgery mainly occurred at the original quadrant. Second breast-conserving surgery did not affect patient' s prognosis. There were significant differences in biological features between the same quadrant recurrence and elsewhere recurrence, requiring different therapeutic strategies in the future.

Evaluating the feasibility of repeat sentinel lymph node biopsy in ipsilateral breast tumor recurrence: Technical considerations and oncologic outcomes

Repeat sentinel lymph node biopsy in patients with ipsilateral recurrent breast cancer after breast-conserving therapy and negative sentinel lymph node biopsy: a prospective study

Clinical characteristics and prognosis of patients with ipsilateral breast tumor recurrence after breast conservation therapy

Lymphoscintigraphy and Single-Photon Emission Computed Tomography (SPECT)/CT to Determine Need for Second Sentinel Lymph Node Biopsy for Breast Cancer Recurrence Following Ipsilateral Breast/Axillary Surgery

Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of Oncology

Surgical Management and Its Impact on Adjuvant Treatment in Recurrent Ipsilateral Breast Cancer: A Retrospective Cohort Study

Sentinel Lymph Node Biopsy after Neoadjuvant Treatment for Breast Cancer. The Validation Protocol

Contribution of SPECT/CT for sentinel node localization in patients with ipsilateral breast cancer relapse

Prevalence and risk factors of intraoperative identification failure of sentinel lymph nodes in patients affected by breast cancer

Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer

Axillary Treatment and Chronic Breast Cancer-Related Lymphedema: Implications for Prospective Surveillance and Intervention From a Randomized Controlled Trial

An exploratory study of whether axillary lymph node dissection can be avoided in breast cancer patients with positive lymph nodes

Axillary Pathologic Complete Response in Inflammatory Breast Cancer Patients: Implications for SLNB?

Current studies and evaluations of sentinel lymph node biopsy for breast cancer

Impact of sentinel lymph node biopsy through the axillary cribriform fascia approach on intraoperative indicators and postoperative complications

Long-term Follow-Up Results of Fluorescence and Blue Dye Guided Sentinel Lymph Node Biopsy in Early Breast Cancer

Narrative review of sentinel lymph node biopsy in breast cancer: a technique in constant evolution with still numerous unresolved questions

The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience

Abstract PO3-23-01: Triple-tracer Technique for Sentinel Lymph Node Biopsy of Breast Cancer after neoadjuvant Chemotherapy using Blue-dye, Radioisotope combined with Real-time Indocyanine green(ICG) Fluorescence Imaging Procrdures

Magnetic Resonance Imaging-Based Prognostic Model for Subsequent Distant Metastasis in Patients with Ipsilateral Breast Tumor Recurrence Following Breast-Conserving Surgery

Sentinel Lymph Node Identification in Patients With Breast Cancer Using Lymphosonography